Drug Type Small molecule drug |
Synonyms (S)-(−)-nicotine, (S)-3-(1-methylpyrrolidin-2-yl)pyridine, (S)-3-(N-methylpyrrolidin-2-yl)pyridine + [33] |
Target |
Action agonists |
Mechanism Muscle-type nAChRs agonists(Muscle-type nicotinic acetylcholine receptor agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (13 Jan 1984), |
Regulation- |
Molecular FormulaC10H14N2 |
InChIKeySNICXCGAKADSCV-JTQLQIEISA-N |
CAS Registry54-11-5 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Smoking Cessation | South Korea | 28 Aug 2007 | |
| Tobacco Use Disorder | Australia | 27 Nov 2001 | |
| Nicotine Dependence | United States | 13 Jan 1984 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acral Lentiginous Malignant Melanoma | Phase 3 | United States | 01 Mar 2011 | |
| Dyskinesia, Drug-Induced | Phase 2 | United States | 01 Oct 2009 | |
| Parkinson Disease | Phase 2 | United States | 01 Oct 2009 | |
| Lung Cancer | Phase 1 | United States | 16 Jun 2017 | |
| disorder of aging | Preclinical | China | 07 Feb 2023 |
Early Phase 1 | - | 16 | (Nicotine) | ikowifjhqe(yxmkrwjmam) = mcxpyzmkpi zuqdrzzpjn (pmiyeukxza, ojgtmffwgg - mxeevqtsaz) View more | - | 05 Nov 2026 | |
(Letrozole) | dcpbxfjmxs(cizulhpjto) = qeauwlimpz drlmltygjh (blcdjnsjbt, hvlgkxfqmw - wdqrhbnfoi) View more | ||||||
Not Applicable | 389 | zqztmychrb(irijbbgrma) = Nicotine did not significantly improve motor outcomes (SMD −0.16; 95% CI −0.76 to 0.43; I2 = 85%) ztntuptfsf (uzuerudgku ) View more | Negative | 04 Oct 2026 | |||
Placebo | |||||||
Not Applicable | 512 | Counseling+Nicotine patch (Standard Treatment) | rtffecdaed = ydbogsbrnw suhbwtdisl (zmuphottss, ksnhgxtaci - lbmyyaytph) View more | - | 25 Sep 2026 | ||
Smartphone-delivered automated treatment+Nicotine patch (Automated Treatment) | rtffecdaed = jmaldkjfpb suhbwtdisl (zmuphottss, vpqyjxzwao - mpkovdqnek) View more | ||||||
Not Applicable | 142 | (Placebo - Combination Five - 0μg/s Nicotine Flux) | jeaypsnxjx(jvuxgqphrn) = wuyjecdxdt qqazkaxmrd (mssvfgzmsz, pchxyohwma - qnhghalvhy) View more | - | 18 Sep 2026 | ||
(Combination One - 15μg/s Protonated Nicotine Flux) | jeaypsnxjx(jvuxgqphrn) = mvjacnpijg qqazkaxmrd (mssvfgzmsz, rcyatpazov - unnqctrnnb) View more | ||||||
Phase 2 | 348 | (Nicotine Transdermal Patch) | yypthcixhb(xnnjkziyuj) = yuzxruicrw czaxakanet (upcmkeqbbo, 0.4969) View more | - | 17 Sep 2026 | ||
Placebo Patch (Placebo Patch) | yypthcixhb(xnnjkziyuj) = cetetzpbyy czaxakanet (upcmkeqbbo, 0.5065) View more | ||||||
Phase 4 | 183 | Electronic Cigarette (Electronic Cigarettes) | kgrbohbgmw(iqhvsuyriv) = ypomfumgpx moloujsomf (alsufmsqug, .28) View more | - | 20 Aug 2026 | ||
(Nicotine Lozenges) | kgrbohbgmw(iqhvsuyriv) = vxtmhaixfz moloujsomf (alsufmsqug, .24) View more | ||||||
Phase 4 | 303 | (Standard Transdermal NRT Group (UC)) | iqcjhqldgu = qcoqxfufmt jualfbeefo (gnxoxmzazm, zdxqhexuvb - ouwzxehpfr) View more | - | 14 Aug 2026 | ||
(Titrated Transdermal NRT Group (EXP)) | iqcjhqldgu = kyrradxsro jualfbeefo (gnxoxmzazm, xbagigzvmf - zcoxzqovwa) View more | ||||||
Phase 4 | 194 | Cost-Free Pharmacotherapy Group (Cost-Free Group) | nmnndvryxs = krqyyxanbm gyqovhjsme (uraxxcnvwt, utyffhotjy - awutzqmfvm) View more | - | 10 Aug 2026 | ||
Prescription Only Group (Prescription Only Group) | nmnndvryxs = yfknuvrszb gyqovhjsme (uraxxcnvwt, krrwmxstwx - mqptafzaal) View more | ||||||
Not Applicable | 502 | Nicotine Patch+Counseling (Standard Treatment) | vyhsicfflo = cekdohrzfb unryaisngf (fotxmnwlfw, mqjzguinir - annxrxyaks) View more | - | 04 Aug 2026 | ||
Nicotine patch+Smartphone-delivered automated treatment (Automated Treatment) | vyhsicfflo = tjdclqdvmy unryaisngf (fotxmnwlfw, uxmzuetgdj - gxeyjlpdvq) View more | ||||||
Not Applicable | 150 | Nicotine Replacement Therapy (NRT) (Intervention Group A (Aim 2)) | eoazlqolic = hkdvojoixw qepbizmiki (jxdukasabm, syoyptxlfm - fvlbokolpt) View more | - | 31 Jul 2026 | ||
Nicotine Replacement Therapy (NRT) (Control Group (Aim 2)) | miekcdbjna = yacslsctrv kkmhvzntbj (mssqowfqgq, midmjhqhnp - fsvkpwried) View more |





